Active, Not Recruiting
BMS-986012 in Relapsed/Refractory SCLC - CA001-030
Updated: 12 November, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histological or cytological confirmed small cell lung cancer (SCLC) - Performance Status 0-1 - Adequate organ function - Measurable disease Exclusion Criteria: - Known or suspected brain metastasis - Small cell cancer not lung in origin - Significant or acute medical illness - Uncontrolled or significant cardiac disease - Infection - ≥ Grade 2 peripheral neuropathy - Concomitant malignancies - HIV related disease or known or suspected HIV+ - Hepatitis B or C infection - ECG abnormalities as defined by the protocol - Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
